Axsome Therapeutics AXSM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$188.3M+32.3% | -$183.17M+36.2% | -$229.53M+26.2% | -$246.9M+20.0% | -$278.27M+6.1% | ||
| $470K-14.4% | $503K-5.5% | $518K-3.4% | $529K-2.2% | $549K+9.6% | ||
| $93.88M+6.3% | $93.75M+10.0% | $93.01M+13.2% | $91.57M+21.6% | $88.34M+26.4% | ||
| $91.98M+53.4% | $84.78M+79.7% | $74.73M+63.6% | $78.48M+48.3% | $59.96M+5.9% | ||
| $13.52M— | $10.66M— | —— | —— | —— | ||
| —— | —— | -$10.03M-129% | $30.29M+64.8% | $31.87M+76.8% | ||
| $100.15M+53.4% | $83.74M+49.4% | $102.24M+145% | $53.32M+5.7% | $65.3M+213% | ||
| $6.38M0.0% | $6.38M-0.3% | $6.38M-0.3% | $6.37M-0.3% | $6.38M-0.3% | ||
| —— | —— | —— | —— | -$108.5K-1,185% | ||
| $795K-70.4% | $1.3M-50.6% | $1.85M-22.5% | $2.36M+1.0% | $2.69M+3.0% | ||
| -$71.78M+39.3% | -$94.45M+26.4% | -$102M+23.1% | -$120.63M+28.0% | -$118.32M+38.6% | ||
| $263K-48.4% | $480K+77.8% | $439K+77.7% | $471K-10.8% | $510K-16.3% | ||
| -$263K+48.4% | -$480K-77.8% | -$439K-77.7% | -$471K+10.8% | -$510K+16.3% | ||
| —— | —— | —— | —— | —— | ||
| $54.6M-5.8% | $67.9M+66.5% | $78.65M+223% | $81.8M+81.7% | $57.93M-77.8% | ||
| $2.4M+95.0% | $2.12M+115% | $1.91M— | $1.56M— | $1.23M— | ||
| $12.08M+81.0% | $7.11M+79.9% | $6.6M+78.4% | $6.23M+74.0% | $6.67M+158% | ||
| $75.19M-14.8% | $101.47M+75.4% | $99.32M+128% | $108.46M+133% | $88.3M-68.3% | ||
| —— | —— | —— | —— | —— | ||
| $12.97M-33.1% | $14.63M-25.7% | $16.33M-17.5% | $18.14M-7.0% | $19.38M+5.2% | ||
| $795K-70.4% | $1.3M-50.6% | $1.85M-22.5% | $2.36M+1.0% | $2.69M+3.0% | ||
| $6.38M0.0% | $6.38M-0.3% | $6.38M-0.3% | $6.37M-0.3% | $6.38M-0.3% | ||
| -$3.4M-111% | -$2.47M-109% | $17.58M-70.9% | $20.79M-52.5% | $31.05M-34.9% | ||
| $470K-14.4% | $503K-5.5% | $518K-3.4% | $529K-2.2% | $549K+9.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$108.5K-1,185% | ||
| $100.15M+53.4% | $83.74M+49.4% | $102.24M+145% | $53.32M+5.7% | $65.3M+213% | ||
| —— | —— | —— | —— | —— | ||
| $3.28M+100% | $3.05M+119% | $2.6M+88.5% | $2.12M+53.7% | $1.64M+9.4% | ||
| $5.97M— | $5.16M— | $8.17M— | —— | —— | ||
| $2.4M+95.0% | $2.12M+115% | $1.91M— | $1.56M— | $1.23M— | ||
| -$10.92M-32.4% | -$9.94M-26.4% | -$9.13M-22.4% | -$8.56M-23.0% | -$8.24M-29.2% | ||
| $899K-25.6% | $1.2M+46.7% | $1.43M— | $1.5M— | $1.21M— | ||
| $52.5M— | $59.56M— | $45.37M— | $50.13M— | —— | ||
| $2.45M+83.6% | $2.19M+111% | $1.97M— | $1.61M— | $1.34M— | ||
| —— | —— | —— | —— | —— | ||
| $6.41M+45.9% | $4.51M-15.8% | $4.86M— | $3.14M— | $4.4M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$71.98M+39.4% | -$94.87M+26.3% | -$102.38M+22.9% | -$121.1M+27.9% | -$118.83M+38.5% | ||
| -$71.98M+39.4% | -$94.87M+26.3% | -$102.38M+22.9% | -$121.1M+27.9% | -$118.83M+38.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Axsome Therapeutics generate?
- Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
- What is Axsome Therapeutics's free cash flow?
- After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
- Where does Axsome Therapeutics's cash flow data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
